IRIDEX CORP

IRIDEX CFO’s June 13 sale shows routine insider trade amid solid gains, hinting at strategic rebalancing while confidence in the company’s ophthalmic laser pipeline stays high.

IRIDEX CFO’s fresh 2,500‑share purchase signals growing confidence in laser‑tech growth and a strategic San Jose move—watch the next earnings for upside.

IRIDEX CFO’s insider buying signals potential upside amid financial distress—investors should watch product launches, cost cuts and regulatory moves.

IRIDEX CFO’s steady buying at market price signals confidence in the VisuLaser™ launch and potential FDA approval, hinting at upside while noting current earnings risks.